"Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat
Synergistic Induction of UCP-1 by Ephedrine/Caffeine and Pioglitazone: A Rationale for Combination Therapy of Obesity
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808
- Pennington Biomedical Research Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- generally healthy
- not pregnant or nursing
- using adequate contraception
- between 18 and 50 years of age
- BMI between 30 and 35 kg/m2
Exclusion Criteria:
- significant renal, cardiac, liver, lung or neurological disease
- high blood pressure
- diabetes
- prior use of thiazolidinedione
- prior use of beta-blockers alcohol or drug abuse
- history of thrombophlebitis, vascular or blood clotting disorders
- unwilling or unable to abstain from caffeinated beverages and alcohol prior to adipose tissue biopsy and metabolic rates measurements
- increased liver function test at baseline
- have metal objects that would interfere with the measurement of the body composition
- use drugs known to affect lipid metabolism, energy metabolism or body weight
- use herbal supplements containing ephedrine and/or caffeine
- take chronic medication, except hormone replacement or contraception
- are a woman unwilling to use effective contraception during the trial
- have heart disease or history of stroke
- have urinary symptoms from enlarged prostate
- have gained and or lost more than 10 pounds in the last 6 month
- have use a monoamine oxidase inhibitor medication in the last month
- have high or low thyroid function that has not been controlled in the normal range for at least 2 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Percent fat after 16 weeks treatment using a Hologic QDR 4500 DEXA.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
UCP-1 gene expression by quantitative RT-PCR
|
|
fat mass, lean mass
|
|
visceral adiposity by multi-slice CT scanning
|
|
resting metabolic rate and thermic effect of a single dose of ephedrine and caffeine
|
|
adipose tissue gene expression profiling using oligonucleotide array
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Overnutrition
- Nutrition Disorders
- Overweight
- Body Weight
- Obesity
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Purinergic Antagonists
- Purinergic Agents
- Phosphodiesterase Inhibitors
- Purinergic P1 Receptor Antagonists
- Central Nervous System Stimulants
- Sympathomimetics
- Vasoconstrictor Agents
- Pioglitazone
- Caffeine
- Ephedrine
Other Study ID Numbers
Other Study ID Numbers
- PBRC 22021
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.